GlobeNewswire

Legend Biotech Announces Presentations at ASCO 2026
21/05/2026
Preliminary results from Phase 1 data for LB2102 to reinforce early evidence of activity in solid tumors in a rapid oral presentation New data from the CARTITUDE-4 study to highlight a cytogenetic subgroup analysis of [...]
Olema Oncology Announces Encouraging Initial Clinical Data from the Phase 1 Study of OP-3136, a KAT6 Inhibitor, at 2026 ASCO Annual Meeting
21/05/2026
OP-3136 monotherapy was well-tolerated with no dose-limiting toxicities observed and no discontinuations due to treatment-related adverse events OP-3136 shows evidence of anti-tumor activity across multiple solid tumor [...]
Compass Therapeutics to Present Promising Phase 1 Clinical Data for CTX-8371 in Patients with Advanced Malignancies Treated in the Post-Checkpoint Inhibitor Setting at the 2026 ASCO Annual Meeting
21/05/2026
CTX-8371, a novel dual checkpoint blocker that simultaneously targets the programmed death receptor PD-1 and its ligand PD-L1, demonstrated promising monotherapy clinical activity in patients with advanced malignancies [...]
Asher Biotherapeutics Announces Two Presentations at the ASCO 2026 Annual Meeting Highlighting Clinical Progress Across Its CD8-Targeted Cytokine Pipeline
21/05/2026
SAN MATEO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Asher Biotherapeutics (Asher Bio), a clinical-stage biotechnology company developing precisely-targeted immunotherapies for cancer, today announced two upcoming [...]
Ficerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep Responses Driven by TGF-β Inhibition in 1L R/M HPV-Negative HNSCC
21/05/2026
At a median follow-up of three years, 1500mg of ficerafusp alfa weekly in combination with pembrolizumab demonstrated an estimated 31% overall survival, approximately doubling OS compared to a retrospective analysis of [...]
Rgenta Therapeutics Presents Positive Preliminary Data from Ongoing Phase 1a/b Clinical Trial of RGT-61159 in Patients with Adenoid Cystic Carcinoma and Colorectal Cancer at the 2026 ASCO Meeting
21/05/2026
Data for patients treated at or below recommended Phase 2 dose (RP2D) showed 84.6% disease control rate (33/39), including 3 partial responses (2 confirmed, 1 pending confirmation) RGT-61159 was well-tolerated at RP2Ds [...]
BlossomHill Therapeutics to Present Preliminary Results From Phase 1 Dose Escalation/Backfill Cohorts in Phase 1/2 SOLARA Trial of OMNI-EGFR Inhibitor, BH-30643, in Advanced EGFR-mutant NSCLC at the 2026 ASCO Annual Meeting
21/05/2026
BH-30643 has demonstrated encouraging clinical activity against diverse EGFR genotypes and on-target resistance in heavily pretreated Phase 1 dose escalation/backfill population with advanced EGFR-mutant NSCLC Responses [...]
HiberCell to Present Preliminary Results from the Phase 1b Trial of GCN2 Activator HC-7366 when Combined with WELIREG® (belzutifan) for the Treatment of Late-Line Clear Cell Renal Cell Carcinoma (ccRCC) at the Upcoming 2026 ASCO Annual Meeting
21/05/2026
Data from Phase 1b dose escalation and expansion trial (n=69) shows a favorable safety profile, with manageable adverse events consistent with the known profiles of the respective drugs. Encouraging preliminary signals [...]
Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy
21/05/2026
- Detailed data from 55 patients to be shared in an oral presentation at the ASCO Annual Meeting on June 1, 2026 - - Tolerability profile consistent with prior updates: only two categories of Grade 3 or higher treatment [...]
Boehringer Ingelheim’s oncology portfolio shows strong promise across multiple cancers at ASCO 2026
21/05/2026
Not intended for US and UK media New patient-reported outcomes data shows improved function and reduced symptom burden with HERNEXEOS ® (zongertinib tablets) as an initial treatment option in HER2 ( ERBB2 )-mutant [...]
Genmab to Highlight Advances Across Its Oncology Portfolio at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2026 Congress
21/05/2026
Media Release COPENHAGEN, Denmark; May 21, 2026 Twenty-three abstracts will highlight the versatility and strength of Genmab’s portfolio and pipeline, including data from the comprehensive epcoritamab development [...]
BulkGLP Announces Dual-Tier Quality Verification Protocol for Global Supply of Analytical Reference Materials
21/05/2026
Exclusive manufacturing partnership integrates point-of-origin batch testing in Malaysia with strict domestic HPLC and LC-MS verification to ensure uncompromising purity for laboratory reagents. BulkGLP Logo DALLAS, May [...]
NMDP Gala in New York City Raises Record-Breaking $660,000 Enabling More Patients to Receive Life-Saving Cell Therapy
21/05/2026
Sanofi Honored with Corporate Leadership Award; Wanda and Robert Zimmer Serve as Honorary Chairs; Sherry Graves Hope Fund for Patient Financial Support Established MINNEAPOLIS, May 21, 2026 (GLOBE NEWSWIRE) -- NMDP℠ [...]
The Joint Corp. Announces Milind Pant Elected as Director
21/05/2026
- Global Executive with Extensive Digital and International Franchise-Led Growth Experience - SCOTTSDALE, Ariz., May 21, 2026 (GLOBE NEWSWIRE) -- The Joint Corp. (NASDAQ: JYNT), the nation's largest franchisor of [...]
IQity and Sightpath Medical Partner to Deliver Advanced Ophthalmic Technology to Surgeons Nationwide
21/05/2026
RENO, Nev., May 21, 2026 (GLOBE NEWSWIRE) -- IQity, the developer of a revolutionary integrated diagnostic and surgical platform for modern ophthalmology, today announced a strategic partnership with Sightpath Medical, [...]
Seven Arrows Recovery Expands Public Education Efforts Around Forward Facing, Nervous System Centered Addiction Treatment
21/05/2026
The Arizona residential treatment center introduces broader awareness of its trauma informed and salutogenic recovery model through Forward Facing Accelerated Recovery™ Elfrida, ARIZONA, May 21, 2026 (GLOBE NEWSWIRE [...]
Paul Cobbo to head leading Brisbane NDIS provider Orange Plan Management
21/05/2026
Brisbane, QUEENSLAND, May 21, 2026 (GLOBE NEWSWIRE) -- Paul Cobbo has been appointed General Manager of nationally recognised NDIS plan manager Orange Plan Management. He brings a decade of experience with him gained [...]
The European Medicines Agency Accepts Teva’s Marketing Authorization Application for Olanzapine Long-Acting Injectable (TEV-‘749) for the Treatment of Schizophrenia in Adults
21/05/2026
The olanzapine long-acting injectable ( TEV-’749) is designed to deliver the efficacy of olanzapine in a subcutaneous formulation 1 administered every four weeks. If approved, TEV-‘749 could help fill a significant [...]
Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Management Services Organization
21/05/2026
WARREN, N.J., May 21, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ) today announced that it has entered into a signed, non-exclusive, non-binding Letter of Intent (“LoI”) to [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum